Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO) released its earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05, FiscalAI reports.

Lexeo Therapeutics Price Performance

NASDAQ:LXEO opened at $5.74 on Wednesday. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $10.99. The firm has a market capitalization of $418.96 million, a PE ratio of -2.62 and a beta of 1.78. The business’s fifty day moving average price is $6.69 and its 200 day moving average price is $7.97.

Insiders Place Their Bets

In related news, CEO Richard Nolan Townsend sold 10,173 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total value of $64,903.74. Following the completion of the sale, the chief executive officer directly owned 392,483 shares of the company’s stock, valued at $2,504,041.54. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $49,650,000. Paradigm Biocapital Advisors LP acquired a new stake in Lexeo Therapeutics during the 4th quarter worth $47,299,000. Vestal Point Capital LP grew its position in Lexeo Therapeutics by 37.7% during the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after purchasing an additional 1,225,000 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Lexeo Therapeutics in the second quarter valued at $16,117,000. Finally, Citadel Advisors LLC raised its holdings in shares of Lexeo Therapeutics by 3.1% in the third quarter. Citadel Advisors LLC now owns 3,719,043 shares of the company’s stock valued at $24,694,000 after buying an additional 111,076 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on LXEO shares. Raymond James Financial initiated coverage on shares of Lexeo Therapeutics in a research note on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price objective for the company. Oppenheimer reiterated an “outperform” rating and set a $20.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, December 10th. HC Wainwright decreased their price target on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Finally, Chardan Capital restated a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.88.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.